中國民航信息網絡股份有限公司
TravelSky Technology Limited

(A joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 00696)

INSIDE INFORMATION ANNOUNCEMENT
KEY OPERATING AND FINANCIAL DATA AS OF MAY 2020; AND PROFIT WARNING FOR THE FIRST HALF OF 2020

This announcement is made by TravelSky Technology Limited (the "**Company**", together with its subsidiaries, the "**Group**") pursuant to Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**").

KEY OPERATING AND FINANCIAL DATA AS OF MAY 2020

Reference is made to the announcement of the Company dated 20 March 2020 in relation to, among others, the influence of the Novel Coronavirus Pneumonia Epidemic (the "**Epidemic**") on business of the Group and key operating data as of February 2020. Since the occurrence of the Epidemic, the People's Republic of China (the "**PRC**") and foreign countries have adopted various strict measures to curb the spread of the Epidemic, and there is significant decline in the number of passenger transportation in civil aviation industry. As of the date of this announcement, the Epidemic continues to spread in overseas areas and clustered epidemic occurred in some particular areas in the PRC. The influence of the Epidemic still remain highly uncertain on aviation industry of the PRC and foreign countries.

The board of the Company (the "**Board**") hereby provides the key operating data from January to May 2020 based on its internal management records in the table below, for the reference by the shareholders of the Company and the potential investors. The future monthly operating data of the Company will be published under the "Operating Data" column on the website of the Company (www.travelskyir.com) established in accordance with the Rule 2.07C(6)(a) of the Listing Rules as usual.

	January to May 2020	January to May 2019	Year-on-year Increase/Decrease
Volume processed by the systems of domestic commercial airlines			
International	10,982,946	41,317,039	-73.42%
Domestic	106,520,138	229,292,363	-53.54%
Total	117,503,084	270,609,032	-56.58%
Volume processed by the systems of international and regional commercial airlines			
Total	1,283,722	10,491,465	-87.76%

The Board also wishes to inform the shareholders of the Company and the potential investors that, based on the internal unaudited consolidated management accounts of the Group, the Group recorded a decrease of 46.5% in the revenue for the five months ended 31 May 2020 compared with the same period of last year. The Board considered that the significant decrease in the revenue compared with the same period of last year was mainly because the PRC and foreign countries have adopted various measures to restrict travel since the occurrence of Epidemic, which led to slump in passengers travel demand and significant decline in the number of passenger transportation in civil aviation industry, resulting in the sharp decline of volume processed by the systems of domestic and international commercial airlines, customers of the Company.

PROFIT WARNING FOR THE FIRST HALF OF 2020

As of the date of this announcement, the duration and extent of the Epidemic around the world still remain highly uncertain, which may aggravate the impact on or lead to the delay of the resumption of demand for air travel. The Board expected the profit after taxation of the Group for the six months ended 30 June 2020 may decrease by approximately 100% (i.e it may record losses) compared with the same period of 2019 based on the preliminary assessment on the internal unaudited consolidated management accounts of the Group and market information currently available.

In order to cope with the adverse impact brought by the Epidemic, the Group has taken a series of measures such as strengthening cost control and resource management while continuing to give full play to its advantages to provide technical support and service guarantee for scientific and technological anti-epidemic. As of the date of this announcement, the balance sheet and financial performance of the Group remain sound. The Company will continue to assess the risks and uncertainties related to the Epidemic, closely follow the changes in market demand, actively respond to the risks and challenges brought by the Epidemic to production and operation of the Group, and strive to mitigate the adverse impact of the Epidemic.

The Board hereby reminds investors that the information contained in this announcement is only preliminary assessment according to the internal management records of the Company and with reference to information currently available, which have not been reviewed or audited by the auditors of the Company and the audit committee of the Company and may be subject to finalization and necessary adjustments. The monthly operating data and relevant financial data disclosed by the Company only serves as preliminary and periodical data for investors' reference, which may differ from the figures to be disclosed in the audited or unaudited consolidated financial statements to be published by the Company on an annual or interim basis. The actual financial results of the Company for the six months ended 30 June 2020, which may differ from those disclosed in this announcement due to changes in the market condition during such period, will be disclosed in the interim results announcement for the six months ended 30 June 2020 which is expected to be published by the end of August 2020. Shareholders of the Company and potential investors should exercise caution when investing or dealing in the shares of the Company.

By the order of the Board
TravelSky Technology Limited
Cui Zhixiong
Chairman

Beijing, PRC
29 June 2020

As at the date of this announcement, the Board comprises:

Executive Directors:	*Mr. Cui Zhixiong (Chairman) and Mr. Xiao Yinhong;*
Non-executive Directors:	*Mr. Zhao Xiaohang, Mr. Xi Sheng and Mr. Luo Laijun;*
Independent non-executive Directors:	*Mr. Cao Shiqing, Dr. Ngai Wai Fung and Mr. Liu Xiangqun.*